Exicure, Inc. Announces Leadership Transition and Changes to the Board of Directors

Author's Avatar
Feb 04, 2022

Exicure, Inc.® (NASDAQ: XCUR), a pioneer in gene regulatory drugs utilizing spherical nucleic acid (SNA™) technology, today announced that Brian C. Bock has submitted his resignation as President and Chief Executive Officer and a member of the Board of Directors of Exicure to pursue a new opportunity. Effective today, Mr. Bock will transition into an advisory role with the Company and will serve as Special Advisor to the Chief Executive Officer to assist during a transition period.